Search alternatives:
significant processes » significant progress (Expand Search), significant promise (Expand Search), significant increases (Expand Search)
processes decrease » progressive decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
significant processes » significant progress (Expand Search), significant promise (Expand Search), significant increases (Expand Search)
processes decrease » progressive decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
-
321
-
322
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
323
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
324
-
325
-
326
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
327
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
328
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
329
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
330
-
331
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
332
-
333
-
334
-
335
-
336
-
337
-
338
An overview of the selection process for studies.
Published 2024“…</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
-
339
-
340